Restricted accessLetterFirst published online 2025-07
Effectiveness,Safety,and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study
NapolitanoM, FabbrociniG, MartoraF, et al.Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022; 35(12):e15901; doi: 10.1111/dth.15901
2.
StingeniL, BianchiL, AntonelliE, et al.A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023; 37(3):e384–e388; doi: 10.1111/jdv.18648
3.
SilverbergJI, SimpsonEL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol., 2013; 24(5):476–486.
4.
El HachemM, NaldiL, NeriI, et al.C. Atopic dermatitis in schoolchildren and adolescents: A critical review of Italian epidemiological data and systemic treatments. Ital J Dermatol Venereol., 2021; 156:650–658.
5.
Italian Republic Official Gazette, n.305, anno 161. Rome, 9 December 2020, 1–56.
6.
KangDH, KwonSH, LewBL. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A Real-World Retrospective Study. J Dermatol. 2024; 51(3):e63–e65; doi: 10.1111/1346-8138.17017
7.
PezzoloE, RossiM, CaroppoF, et al.Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A Real-World Prospective Cohort Study. J Eur Acad Dermatol Venereol. 2023; 37(6):e757–e759; doi: 10.1111/jdv.18889
8.
SpekhorstLS, AriënsLFM, van der SchaftJ, et al.Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the bioday registry. Allergy. 2020; 75(9):2376–2379; doi: 10.1111/all.14324
9.
NapolitanoM, MarianoM, CristaudoA, et al.Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: A Multicenter Study. J Dermatolog Treat. 2022; 33(5):2670–2673; doi: 10.1080/09546634.2022.2067818
